Short answer
Krystal Biotech, Inc. (KRYS) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $119M (up 24.1% year over year) with net income of $55M.
Q2 2026 key financials · XBRL
- Revenue
- $119M
- +24.1% YoY · +2.5% QoQ
- Net income
- $55M
- +42.9% YoY · −2.1% QoQ
- Operating margin
- 49.0%
- EPS (diluted)
- $1.79
- +39.8% YoY · −2.2% QoQ
Source: XBRL data from the Krystal Biotech, Inc. (KRYS) Q2 2026 10-Q on SEC EDGAR. USD.
Krystal Biotech, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in the supplied excerpt
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Krystal Biotech, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.